Page last updated: 2024-09-05

muraglitazar and Fatty Liver, Nonalcoholic

muraglitazar has been researched along with Fatty Liver, Nonalcoholic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amaudrut, J; Barth, M; Binet, J; Boubia, B; Broqua, P; Chatar, M; Dodey, P; Ferry, S; Gauthier, E; Guillier, F; Jacquier, E; Junien, JL; Lacombe, O; Legendre, C; Lepais, V; Llacer, J; Luccarini, JM; Masson, P; Montalbetti, C; Mounier, L; Peralba, P; Poupardin, O; Thourigny, A; Wettstein, G	1
Anthérieu, S; Claude, N; de la Moureyre-Spire, C; Guillouzo, A; Rogue, A; Umbdenstock, T; Vluggens, A; Weaver, RJ	1

Other Studies

2 other study(ies) available for muraglitazar and Fatty Liver, Nonalcoholic

Article	Year
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. Journal of medicinal chemistry, 2018, 03-22, Volume: 61, Issue:6 Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides	2018
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicology and applied pharmacology, 2014, Apr-01, Volume: 276, Issue:1 Topics: Cell Line; Constitutive Androstane Receptor; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Glycine; Humans; Lipid Metabolism; Lipogenesis; Lipotropic Agents; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Oleic Acid; Orphan Nuclear Receptors; Oxazoles; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Triglycerides	2014

Article

Year

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Journal of medicinal chemistry, 2018, 03-22, Volume: 61, Issue:6

Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides

2018

PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.

Toxicology and applied pharmacology, 2014, Apr-01, Volume: 276, Issue:1

Topics: Cell Line; Constitutive Androstane Receptor; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Glycine; Humans; Lipid Metabolism; Lipogenesis; Lipotropic Agents; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Oleic Acid; Orphan Nuclear Receptors; Oxazoles; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Triglycerides

2014